Antibody Ingredients TRIZ Cases

Novel antibody conjugates bind variant NFKBIB antigens on cancer cells to deliver targeted therapeutic agents.

Engineered antibody CDR sequences bind VEGFR2 with high affinity to inhibit endothelial cell proliferation.

A bispecific polypeptide links tumor cells to cytotoxic T-cells for targeted immune activation.

Bi-specific antibodies merge anti-CD137 agonists with anti-PD-1 blockers to enhance T cell stimulation while reducing safety concerns.

Antibodies bind ED-A fibronectin in tumor metastasis neovasculature, disrupting blood flow and depriving tumors of oxygen.

Modifying variable region amino acid sequences reduces immunogenicity while maintaining therapeutic efficacy against tumors.

Optimized fully human monoclonal antibodies bind tissue factor pathway inhibitor to restore coagulation function.

IL-17 Receptor A antigen binding proteins block inflammatory signaling, overcoming poor topical penetration and improving scalp and nail psoriasis symptoms.

High affinity human monoclonal antibodies inhibit LAG-3 binding to MHC Class II molecules, resolving insufficient T cell stimulation in immunotherapy.

Combines allergen-specific IgG with anti-IgE antibodies to block hypersensitivity reactions.

Heterodimeric Fc proteins with targeted mutations improve ADCC and ADCP activities by increasing FcγRIIIA binding affinity.

Durvalumab blocks PD-L1 binding to restore T cell activity, extending median progression-free survival from 5.6 months to 16.8 months after chemoradiation.

A bispecific antibody binds human IL-18 receptor alpha and beta subunits to activate signaling pathways.

SCD modulating compounds target SCD1 and SCD5 enzymes to overcome limited relief from current Parkinson's and Alzheimer's therapies.

Measuring glucosylsphingosine abundance enables accurate frontotemporal dementia risk identification and therapeutic response tracking.

Modifies glycosylation of anti-CD20 antibody to reduce fucose content, addressing high toxicity while maintaining therapeutic efficacy in cancer treatment.

Full-length CD70 antibodies resolve short half-life constraints by minimizing non-specific cytokine release for safer renal cell carcinoma treatment.

Humanized anti-CD40 antibody binds specific agonistic epitopes to activate antigen-presenting cells without interfering with CD40L interaction.

Bispecific antibody blocks PD-L1 and LAG3 interactions, reversing regulatory T cell suppression to enhance anti-tumor immune responses.

Eblasakimab targets the IL-13Rα1 receptor to treat moderate to severe atopic dermatitis resistant to dupilumab.

Cationized antibodies form stable ionic liquids through lyophilization and ion pairing.

Multispecific antibodies bind PSMA and CD3 to redirect T cells, resolving limited antibody specificity in prostate cancer therapy.

Biodegradable polymeric implants deliver anti-interleukin 6 agents and vitamin A analogues to the tumor bed.

CD38 modulating antibodies resolve low solid tumor expression by activating immune effector cells via enhanced ADCC and reduced CDC.

Local quality modifications in antibody variable regions reduce autoimmune side effects while maintaining high binding affinity and therapeutic effectiveness.

Agonist anti-CD27 antibodies overcome limited PD-1 therapy response rates by synergizing with checkpoint inhibitors.

Affinity-matured MICA antibodies inhibit protein shedding and bridge natural killer cells to tumors, overcoming immune evasion in cold cancers.

Engineered antibodies neutralize Siglec-9 inhibitory signaling, resolving the trade-off between receptor binding and effective tumor cell elimination.

Segmenting binding domains into a single molecule merges anti-CD79b and anti-CD3 functions to overcome resistance in non-Hodgkin lymphoma.

Modifying the Fc domain to exclude FcγRI and FcγRIII binding reduces cytokine release and off-target cytotoxicity while preserving antitumor potency.

Chimeric and humanized anti-CD37 antibodies resolve immunogenicity risks while maintaining therapeutic efficacy for B-cell malignancies.

Optimized chimeric antibody structures resolve binding affinity limitations against human CD48 while maintaining therapeutic specificity.

A triple-specific nanobody binds HLA-G, PD-L1, and CD3ε to activate T cells.

Antibodies agonize MERTK signaling on endothelial cells to inhibit angiogenesis while sparing cancer cell metastasis.

Combination therapy removes atheromas by addressing insulin resistance, lipid levels, and inflammation to treat coronary artery disease.

Compounds promote premature termination codon read-through and inhibit nonsense-mediated decay to express neoantigens on cancer cells.

Antibodies isolate glioblastoma stem-like cells to resolve suboptimal marker sensitivity and improve diagnostic accuracy.

Agonistic antibodies trigger MERTK signaling in endothelial cells, blocking angiogenesis and metastasis while suppressing tumor growth.

Glycosylation modification of anti-ErbB3 antibodies resolves efficacy and specificity trade-offs to inhibit tumor growth.

Anti-NRP-1 antibodies target glycosaminoglycan-modified epitopes to induce nuclear entry and DNA damage in cancer cells.

Targeting CXCR5 reduces autoantibody production without causing immunocompromise, resolving selectivity issues in lupus therapy.

Segmented multispecific antibodies targeting EGFR and HER3 reduce dermatological toxicity while inhibiting tumor growth.

Monoclonal antibody h6F10 binds long and short VSIG4 isoforms via optimized CDRs, resolving partial inhibition by suppressing anti-inflammatory signals.

ADAM12 inhibitors deplete stromal cells to disrupt the tumor capsule, improving perfusion and immune infiltration against treatment resistance.

An antibody targeting the AITR epitope converts T cells into TH17 cells.

Combining pre-targeted radioimmunotherapy with CD40 agonists and PD-L1 inhibitors overcomes limited efficacy and rapid tumor growth in refractory cancer cases.

An EpCAM-targeting immunoconjugate delivers a cytotoxic agent directly to bladder cancer cells via instillation.

Humanized antibodies bind specific PD-1 patches to restore T-cell function, resolving exhaustion in HIV and cancer treatments.

Fully human antibodies bind VEGFR2 epitopes to block angiogenesis, resolving specificity and efficacy trade-offs in cancer therapy.